Carvedilol induces greater control of β2- than β1-adrenoceptor-mediated inotropic and lusitropic effects by PDE3, while PDE4 has no effect in human failing myocardium

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 387, Issue 7, 2014, Pages 629-640

  Molenaar, Peter ^a,e   Christ, Torsten ^b,d   Berk, Emanuel ^b   Engel, Andreas ^b   Gillette, Katherine T ^a,e   Galindo Tovar, Alejandro ^c   Ravens, Ursula ^b   Kaumann, Alberto J ^c  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Carvedilol; Human heart failure; Inotropism and lusitropism; Noradrenaline and adrenaline; Phosphodiesterases 3 and 4

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; 5 [2 [[2 HYDROXY 3 [4 (1 METHYL 4 TRIFLUOROMETHYL 2 IMIDAZOLYL)PHENOXY]PROPYL]AMINO]ETHOXY]SALICYLAMIDE; ADRENALIN; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; CARVEDILOL; CILOSTAMIDE; NORADRENALIN; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IV; ROLIPRAM; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAZOLE DERIVATIVE; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; PROPANOLAMINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SELECTIVITY; FEMALE; HEART FAILURE; HEART MUSCLE RELAXATION; HEART PROTECTION; HEART RIGHT VENTRICLE; HUMAN; HUMAN TISSUE; INOTROPISM; LUSITROPIC EFFECT; MALE; HEART TRANSPLANTATION; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADRENERGIC BETA-ANTAGONISTS; ADULT; CARBAZOLES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; EPINEPHRINE; FEMALE; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; NOREPINEPHRINE; PHOSPHODIESTERASE 3 INHIBITORS; PHOSPHODIESTERASE 4 INHIBITORS; PROPANOLAMINES; QUINOLONES; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-2; ROLIPRAM;

EID: 84904130391     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-014-0974-4     Document Type: Article

References (51)

1. Amsallem E, Kasparian C, Haddour G, Boissel JP, Nony P (2005) Phosphodiesterase III inhibitors for heart failure. Cochrane Database Syst Rev Jan 25; (1): CD002230
2. Anderson JL (1991) Hemodynamic and clinical benefits with intravenous milrinone in severe chronic heart failure: results of a multicenter study in the United States. Am Heart J 121:1956-1964
3. 3- adrenoceptors. Br J Pharmacol 144:317-322
4. Bender AT, Beavo JA (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58:488-520 (Pubitemid 44394910)
5. Bristow MR (2000) β-Adrenergic receptor blockade in chronic heart failure. Circulation 101:558-569
6. 2-adrenergic receptor-mediated adenylate cyclase stimulation in non-failing and failing human myocardium. Mol Pharmacol 35:295-303
7. 2-adrenoceptors in patients with primary electrical cardiac abnormalities. J Am Coll Cardiol 26:864-869
8. 1-adrenoceptors in human atrial myocardium. Naunyn-Schmiedeberg's Arch Pharmacol 374:249-253
9. 2-adrenergic stimulation in the failing heart are attributable to enhanced sarcoplasmic reticulum Ca load. Circ Res 102:1389-1397
10. Di Lenarda A, Sabbadini G, Salvatore L, Sinagra G, Mestroni L, Pinamonti B, Gregori D, Ciani F, Muzzi A, Klugmann S, Camerini F (1999) Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. The Heart-Muscle Disease Study Group. J Am Coll Cardiol 33:1926-1934
11. Eschenhagen (2013) PDE4 in the human heart - major player or little helper? Br J Pharmacol 169:524-527
12. Galindo-Tovar A, Kaumann AJ (2008) Phosphodiesterase-4 blunts inotropism and arrhythmias but not sinoatrial tachycardia of (-)-adrenaline mediated through mouse cardiac β1-adrenoceptors. Br J Pharmacol 153:710-720 (Pubitemid 351271768)
13. Gettys TW, Blackmore PF, Redmon JB, Beebe SJ, Corbin JD (1987) Short-term feedback regulation of cAMP by accelerated degradation in rat tissues. J Biol Chem 262:333-339 (Pubitemid 17000025)
14. Gilbert EM, Abraham WT, Olsen S, Hattler B, White M, Mealy P, Larrabee P, Bristow MR (1996) Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 94:2817-2825 (Pubitemid 26411746)
15. 2-adrenoceptors of human heart. Differential antagonism of the positive inotropic effects and adenylate cyclase stimulation by (-)-noradrenaline and (-)-adrenaline. Naunyn Schmiedebergs Arch Pharmacol 331:60-67
16. 2-adrenergic receptors display subtype-selective coupling to Gs. Mol Pharmacol 41:889-893
17. Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB (1989) Increased β-receptor density and improved hemodynamic responses to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation 70:483-490 (Pubitemid 19087699)
18. Kaumann AJ (2011) Phosphodiesterases reduce spontaneous sinoatrial beating but not the 'fight or flight' tachycardia elicited by agonists through Gs-protein coupled receptors. Trends Pharmacol Sci 32:377-383
19. 2-adrenergic receptors hastens relaxation and mediates phosphorylation of phospholamban, troponin I, and C-protein in ventricular myocardium from patients with terminal heart failure. Circulation 99:65-72
20. 2-adrenoceptor-mediated positive inotropic effect of adrenaline in human ventricular myocardium. Quantitative discrepancies with binding and adenylate cyclase stimulation. Naunyn Schmiedebergs Arch Pharmacol 335:403-411
21. 2-adrenoceptors. Pharmacol Commun 6:215-222
22. 2-adrenoceptors mediate catecholamine-evoked arrhythmias in isolated human right atrium. Naunyn Schmiedebergs Arch Pharmacol 348:536-540
23. 2-Adrenoceptor activation by zinterol causes protein contractile effects and relaxant effects through a cAMP pathway in human atrium. Mol Cell Biochem 163-164:113-123
24. 1- adrenoceptors, are reduced by PDE3 in human atrium but PDE4 in CHO cells. Naunyn Schmiedebergs Arch Pharmacol 375:123-131
25. s and Gi. Circ Res 87:635-639
26. Kindermann M, Maack C, Schaller S, Finkler N, Schmidt KI, Läer S, Wuttke H, Schäfers H-J, Böhm M (2004) Carvedilol but not metoprolol reduces β-adrenergic responsiveness after complete elimination from plasma in vivo. Circulation 109:3182-3190
27. Lehnhart SE, Wehrens XH, Reiken S, Warrier S, Belevych AE, Harvey RD, Richter W, Jin S-LC, Conti M, Marks AR (2005) Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell 123:25-35 (Pubitemid 41414526)
28. 2-adrenergic receptors. Proc Natl Acad Sci U S A 90:10798-10802
29. Li XD, Wang JC, Zhao Y, Zhou NN, Zhu X (2010) Effects of carvedilol and metoprolol on expression of autoantibodies against cardiac adrenergic receptors in aged patients with chronic heart failure and ventricular arrhythmias. Chin J Cardiol 38:584-587
30. Lugnier C, Muller B, Le Bec A, Beaudry C, Rousseau E (1993) Characterization of indolidan- and rolipram-sensitive cyclic nucleotide phosphodiesterases in canine and human cardiac microsomal fractions. J Pharmacol Exp Ther 265:1142-1151 (Pubitemid 23321013)
31. Mehel H, Emons J, Vettel C, Wittköpper K, Seppelt D, Dewenter M, Lutz S, Sossalla S, Maier LS, Lechêne P, Leroy J, Lefebvre F, Varin A, Eschenhagen T, Nattel S, Dobrev D, Zimmermann WH, Nikolaev VO, Vandecasteele G, Fischmeister R, El-Armouche A (2013) Phosphodiesterase-2 is up-regulated in human failing hearts and blunts β-adrenergic responses in cardiomyocytes. J Am Coll Cardiol 62:1596-1606
32. s-protein. Circulation 102:1814-1821
33. 2-adrenoceptor-mediated inotropic and lusitropic effects in failing ventricle from metoprolol-treated patients. Br J Pharmacol 169:528-538
34. 1-adrenoceptors in human heart. Cardiovasc Res 69:128-139
35. i coupling. Naunyn Schmiedebergs Arch Pharmacol 375:11-28
36. Molina CE, Leroy J, Richter W, Xie M, Scheitrum C, Lee IO, Maack C, Rucker-Martin C, Donzeau-Gouge P, Verde I, Llach A, Hove-Madsen L, Conti M, Vandecasteele G, Fischmeister R (2012) Cyclic adenosine monophosphate phosphodiesterase type 4 protects against atrial arrhythmias. J Am Coll Cardiol 59:2182-2190
37. Movsesian MA, Smith CJ, Krall J, Bristow MR, Manganiello VC (1991) Sarcoplasmic reticulum-associated cyclic adenosine 5′-monophosphate phosphodiesterase activity in normal and failing human hearts. J Clin Invest 88:15-19
38. i-proteins in heart failure. Lancet 2:936-937
39. 2-adrenergic receptor-mediated signaling. Circ Res 99:1084-1091
40. 2-Adrenergic receptor redistribution in heart failure changes cAMP compartmentation. Science 327:1653-1657
41. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK, DeMets DL (1991) Effect of oral milrinone on mortality in severe chronic heart failure. The Promise Study Research Group. N Engl J Med 325:1468-1475
42. Perera RK, Nikolaev VO (2013) Compartmentation of cAMP signalling in cardiomyocytes in health and disease. Acta Physiol 207:650-662
43. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajada M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A, Carvedilol or Metoprolol European Trial Investigators (2003) Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomized control trial. Lancet 362:7-13, For the COMET investigators (Pubitemid 36835815)
44. Remme WJ, Cleland JG, Erhardt, Spark P, Torp-Pedersen C, Metra M, Komajda M, Moullet C, Lukas MA, Poole-Wilson P, Di Lenarda A, Swedberg K (2007) Effect of carvedilol andmetoprolol on themode of death in patients with heart failure. Eur J Heart Failure 9:1128-1135 (Pubitemid 350011059)
45. Reves JG, Karp RB, Buttner EE, Tosone S, Smith LR, Samuelson PN, Kreusch GR, Oparil S (1982) Neuronal and adrenomedullary catecholamine release in response to cardiopulmonary bypass in man. Circulation 66:49-55 (Pubitemid 12069956)
46. Richter W, Xie M, Scheitrum C, Krall J, Movsesian MA, Conti M (2011) Conserved expression and functions of PDE4 in rodent and human heart. Basic Res Cardiol 106:249-262
47. Rickham PP (1964) Human experimentation. Code of ethics of the World Medical Association. Declaration of Helsinki. Br Med J 2:177
48. iα-proteins in patients with congestive heart failure. Eur J Clin Pharmacol 51:127-132
49. Van Tassel BW, Radwanski P, Movsesian M, Munger MA (2008) Combination therapy with β-adrenergic receptor antagonists and phosphodiesterase inhibitors for chronic heart failure. Pharmacotherapy 28:1523-1530
50. Wittstein IS, Thiemann DR, Lima JAC, Baughman KL, Schulman SP, Gerstenblith G, Wu KC, Rade JJ, Bivalacqua TJ, Champion HC (2005) Neurohumoral features of myocardial stunning due to sudden emotional stress. N Eng J Med 352:539-548 (Pubitemid 40204667)
51. Wortsman J (2002) Role of epinephrine in acute stress. Endocrinol Metab Clin North Am 31:79-106